immunosuppressive agents

Preferred Label : immunosuppressive agents;

MeSH definition : Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.;

MeSH synonym : agents, immunosuppressive; immunosuppressants; Immunosuppressive Agent; Agent, Immunosuppressive; Immunosuppressant;

Wikipedia automatic translation : Immunosuppressive drug;

Wikipedia link : https://en.wikipedia.org/wiki/Immunosuppressive drug;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D007166;

UMLS CUI

C0021081;

ATC code(s)
- mycophenolic acid [ATC Code]
- pegcetacoplan [ATC Code]
ATC code(s)
- Janus-associated kinase (JAK) inhibitors [ATC Code]
- Mammalian target of rapamycin (mTOR) kinase inhibitors [ATC Code]
- abatacept [ATC Code]
- antithymocyte immunoglobulin (rabbit) [ATC Code]
- azathioprine [ATC Code]
- basiliximab [ATC Code]
- calcineurin inhibitors [ATC Code]
- ciclosporin [ATC Code]
- daclizumab [ATC Code]
- etanercept [ATC Code]
- everolimus [ATC Code]
- gusperimus [ATC Code]
- immunosuppressants [ATC Code]
- immunosuppressants [ATC Code]
- leflunomide [ATC Code]
- methotrexate [ATC Code]
- muromonab-cd3 [ATC Code]
- mycophenolic acid [ATC Code]
- other immunosuppressants [ATC Code]
- selective immunosuppressants [ATC Code]
- sirolimus [ATC Code]
- tacrolimus [ATC Code]
- thalidomide [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Immunosuppressant poisoning (disorder) [SNOMED CT concept]
False automatic mappings
- Immunosuppressive agents [ICD-10 Sub-category (who)]
- immunosuppression [Disease (Nov.)]
Indexing information
- 1,3-dicyclopentyl-1,2,3,6-tetrahydropyrimidine-4,5-dicarboxylic acid diethyl ester [MeSH Supplementary Concept]
- 2-(2-benzothiazoleyl)-4,5,6,7-tetrahydro-2H-indazol-3-ol [MeSH Supplementary Concept]
- C4-mycophenolic adenine dinucleotide [MeSH Supplementary Concept]
- CopA3 peptide, copris tripartitus [MeSH Supplementary Concept]
- FR 901483 [MeSH Supplementary Concept]
- Fr.5-B, bacillus stearothermophilus UK563 component [MeSH Supplementary Concept]
- HT29 factor [MeSH Supplementary Concept]
- N-(3,5-bis(trifluoromethyl)phenyl)-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide [MeSH Supplementary Concept]
- actinotetraose E [MeSH Supplementary Concept]
- adefovir [MeSH Supplementary Concept]
- bleselumab [MeSH Supplementary Concept]
- cell-mediated immune function inhibitor [MeSH Supplementary Concept]
- cytolethal distending toxin [MeSH Supplementary Concept]
- ditritiocorreolide [MeSH Supplementary Concept]
- gallium nitrate [MeSH Supplementary Concept]
- liver suppressor factor 1 [MeSH Supplementary Concept]
- macrophage-derived immunosuppressor factor [MeSH Supplementary Concept]
- paquinimod [MeSH Supplementary Concept]
- pirarubicin [MeSH Supplementary Concept]
- suppressive factor of allergy [MeSH Supplementary Concept]
- tolerogen [MeSH Supplementary Concept]
- vaticaffinol [MeSH Supplementary Concept]
Record concept(s)
- immunosuppressive agents [MeSH concept]
See also
- antilymphocyte serum [MeSH Descriptor]
- antirheumatic agents [MeSH Descriptor]
See also (suggested by CISMeF)
- Immunosuppression Therapy [MeSH Descriptor]
See also inter- (CISMeF)
- Medicinal product acting as immunosuppressant (product) [SNOMED CT concept]
Semantic type(s)
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- (T,G)-A-L [MeSH Supplementary Concept]
- 2-acetyl-4(5)-tetrahydroxybutylimidazole [MeSH Supplementary Concept]
- 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole [MeSH Supplementary Concept]
- 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol [MeSH Supplementary Concept]
- 5-mercapto-2'-deoxyuridine [MeSH Supplementary Concept]
- 8-aminoguanosine [MeSH Supplementary Concept]
- 9-(2-hydroxy-3-nonyl)adenine [MeSH Supplementary Concept]
- 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine [MeSH Supplementary Concept]
- Abatacept [MeSH Descriptor]
- BCRF1 protein, human herpesvirus 4 [MeSH Supplementary Concept]
- Basiliximab [MeSH Descriptor]
- Certolizumab Pegol [MeSH Descriptor]
- Daclizumab [MeSH Descriptor]
- Dimethyl Fumarate [MeSH Descriptor]
- Etanercept [MeSH Descriptor]
- Everolimus [MeSH Descriptor]
- FR 167653 [MeSH Supplementary Concept]
- FX006 [MeSH Supplementary Concept]
- Glatiramer Acetate [MeSH Descriptor]
- KH 1060 [MeSH Supplementary Concept]
- L-glutamic acid-L-tyrosine copolymer [MeSH Supplementary Concept]
- Leflunomide [MeSH Descriptor]
- Mercaptopurine [MeSH Descriptor]
- Muromonab-CD3 [MeSH Descriptor]
- N,N'-dimethylnitrosourea [MeSH Supplementary Concept]
- OM 89 [MeSH Supplementary Concept]
- ONO-LB 457 [MeSH Supplementary Concept]
- PAEP protein, human [MeSH Supplementary Concept]
- SDZ IMM 125 [MeSH Supplementary Concept]
- SK&F 105685 [MeSH Supplementary Concept]
- SR 31747 [MeSH Supplementary Concept]
- U 74389F [MeSH Supplementary Concept]
- U 74500A [MeSH Supplementary Concept]
- Wortmannin [MeSH Descriptor]
- X 910279 [MeSH Supplementary Concept]
- abetimus [MeSH Supplementary Concept]
- acteoside [MeSH Supplementary Concept]
- adalimumab biosimilar HS016 [MeSH Supplementary Concept]
- alicaforsen [MeSH Supplementary Concept]
- antilymphocyte serum [MeSH Descriptor]
- azaserine [MeSH Descriptor]
- azathioprine [MeSH Descriptor]
- azodicarbonamide [MeSH Supplementary Concept]
- belimumab [MeSH Supplementary Concept]
- benzonidazole [MeSH Supplementary Concept]
- bestrabucil [MeSH Supplementary Concept]
- bis(p-chlorophenyl)acetic acid [MeSH Supplementary Concept]
- bis(tri-n-butyltin)oxide [MeSH Supplementary Concept]
- brequinar [MeSH Supplementary Concept]
- butenolide [MeSH Supplementary Concept]
- castanospermine [MeSH Supplementary Concept]
- cladribine [MeSH Descriptor]
- coformycin [MeSH Descriptor]
- cyclolinopeptide A [MeSH Supplementary Concept]
- cyclosporin G [MeSH Supplementary Concept]
- cyclosporine [MeSH Descriptor]
- cyclosporins [MeSH Descriptor]
- cytarabine [MeSH Descriptor]
- daltroban [MeSH Supplementary Concept]
- dan-shen root extract [MeSH Supplementary Concept]
- deflazacort [MeSH Supplementary Concept]
- desthiobiotin [MeSH Supplementary Concept]
- dibutyldichlorotin [MeSH Supplementary Concept]
- didemnins [MeSH Supplementary Concept]
- dimethyl sulfate [MeSH Supplementary Concept]
- doxifluridine [MeSH Supplementary Concept]
- early pregnancy factor [MeSH Supplementary Concept]
- ellipticines [MeSH Descriptor]
- enisoprost [MeSH Supplementary Concept]
- fludarabine phosphate [MeSH Supplementary Concept]
- fluorouracil [MeSH Descriptor]
- glimepiride [MeSH Supplementary Concept]
- gliotoxin [MeSH Descriptor]
- golimumab [MeSH Supplementary Concept]
- gusperimus [MeSH Supplementary Concept]
- hypericin [MeSH Supplementary Concept]
- immunomycin [MeSH Supplementary Concept]
- inolimomab [MeSH Supplementary Concept]
- leucyl-leucine-methyl ester [MeSH Supplementary Concept]
- leukotoxin [MeSH Supplementary Concept]
- lisofylline [MeSH Supplementary Concept]
- lobenzarit [MeSH Supplementary Concept]
- methotrexate [MeSH Descriptor]
- methoxyacetic acid [MeSH Supplementary Concept]
- methyl cellosolve [MeSH Supplementary Concept]
- mizoribine [MeSH Supplementary Concept]
- monodansylcadaverine [MeSH Supplementary Concept]
- peficitinib [MeSH Supplementary Concept]
- pimecrolimus [MeSH Supplementary Concept]
- pirmagrel [MeSH Supplementary Concept]
- pristane [MeSH Supplementary Concept]
- repirinast [MeSH Supplementary Concept]
- rozanolixizumab [MeSH Supplementary Concept]
- saikosaponin D [MeSH Supplementary Concept]
- semapimod [MeSH Supplementary Concept]
- seocalcitol [MeSH Supplementary Concept]
- sirolimus [MeSH Descriptor]
- stepronin [MeSH Supplementary Concept]
- tacrolimus [MeSH Descriptor]
- tanshinone [MeSH Supplementary Concept]
- tepoxalin [MeSH Supplementary Concept]
- teriflunomide [MeSH Supplementary Concept]
- tetrandrine [MeSH Supplementary Concept]
- thalidomide [MeSH Descriptor]
- thermozymocidin [MeSH Supplementary Concept]
- thioinosine [MeSH Descriptor]
- thymoglobulin [MeSH Supplementary Concept]
- tobacco tar [MeSH Supplementary Concept]
- traxanox [MeSH Supplementary Concept]
- triamcinolone acetonide [MeSH Descriptor]
- triptolide [MeSH Supplementary Concept]
- trofosfamide [MeSH Supplementary Concept]
- umirolimus [MeSH Supplementary Concept]
- undecylprodigiosin [MeSH Supplementary Concept]
- uterine luminal fluid proteins [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Immunosuppressant [NCIt concept]
- Immunosuppressant (substance) [SNOMED CT concept]
- Immunosuppressive agents [Bloc CIM-11]
- Immunosuppressive drug [ICD-11 Extension code]
- Immunosuppressives [LOINC hierarchical part]
- Medicinal product acting as immunosuppressant (product) [SNOMED CT concept]
- immunosuppressant agent, nos [SNOMED Notion]
- immunosuppressants [ATC Code]
- immunosuppressants [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients